Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed reports 11% revenue growth to $1.2 billion for quarter ended September 30, 2024

Positive Impact 3 of 5 earnings Written later

ResMed reported fiscal first-quarter 2025 results, with revenue up 11% to $1.2 billion, income from operations up 34%, and diluted earnings per share of $2.11, up 42% from $1.49. The company also declared a quarterly cash dividend of $0.53 per share, with a November 7, 2024 record date and December 12, 2024 payment date.

Key points

  • Revenue rose 11% to $1.2 billion; gross margin improved 420 basis points to 58.6%.
  • Diluted EPS was $2.11 (GAAP) and $2.20 (non-GAAP), versus $1.49 and $1.64 a year earlier.
  • Quarterly cash dividend of $0.53 per share; ex-dividend date November 6, 2024, payable December 12, 2024.
  • Operating cash flow was $326 million; the company repurchased $50 million of stock during the quarter.

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECOct 24, 2024, 4:05 PM ET
Accession number0001193125-24-242806

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 24, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.